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Abstract
Friedreich ataxia (FA) is a rare disease caused by deficiency of frataxin, a mitochondrial protein. As there is no cure available for this disease,
many strategies have been developed to reduce the deleterious effects of such deficiency. One of these approaches is based on delivering fra-
taxin to the tissues by coupling the protein to trans-activator of transcription (TAT) peptides, which enables cell membranes crossing. In this
study, we tested the efficiency of TAT-MTScs-FXN fusion protein to decrease neurodegeneration markers on frataxin-depleted neurons obtained
from dorsal root ganglia (DRG), one of the most affected tissues. In mice models of the disease, we tested the ability of TAT-MTScs-FXN to
penetrate the mitochondria and its effect on lifespan. In DRG neurons, treatment with TAT-MTScs-FXN increased cell survival, decreased neurite
degeneration and reduced apoptotic markers, such as a-fodrin cleavage and caspase 9 activation. Also, we show that heat-shock protein 60
(HSP60), a molecular chaperone targeted to mitochondria, suffered an impaired processing in frataxin-deficient neurons that was relieved by
TAT-MTScs-FXN addition. In mice models of the disease, administration of TAT-MTScs-FXN was able to reach muscle mitochondria, restore
the activity of the succinate dehydrogenase and produce a significant lifespan increase. These results support the use of TAT-MTScs-FXN as a
treatment for Friedreich ataxia.
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Introduction
Friedreich ataxia (FA) is the most common autosomal recessive ataxia
known to date, with a population frequency of 1–2/50,000 [1] and
early life mortality caused mainly by cardiomyopathy [2]. FA is attrib-
uted to partial depletion of the mitochondrial protein Frataxin, caused
by a trinucleotide GAA expansion in intron 1 of the Frataxin gene.
When both Frataxin alleles contain the intron 1 expansion, frataxin
level is reduced below the normal threshold and FA is overt [3]. Addi-
tionally, increased number of GAA repeats (100–1700 in FA patients)
is associated with more severe clinical outcome [2]. Frataxin is a
nuclear encoded protein that is translocated to the mitochondria due
to a mitochondrial targeting sequence (MTS) that is expressed on its
N-terminus [4, 5]. Frataxin biological function is not completely eluci-
dated; however, it was found to regulate the biogenesis of
mitochondrial Fe-S clusters [6, 7] Fe-S clusters serve as prosthetic
groups for a series of enzymes including, among others, energy
metabolism enzymes such as aconitase [8] or proteins of the respira-
tory chain including succinate dehydrogenase [9]. These enzymes
were found to be impaired in FA patients [10]. Nevertheless, frataxin
may have additional roles as Fe-S deficiency is not a universal conse-
quence of frataxin deficiency [11, 12].
Leading drug candidates for FA are now in phase 2 clinical trials,
but currently, no cure is available. Drug candidates include, among
others, mitochondrial function enhancers, antioxidant and neuropro-
tection agents, enhancers of frataxin gene expression and frataxin
replacement. The latter consists in delivering frataxin to cells using
the HIV-trans-activator of transcription (TAT) as carrier molecule
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[13]. Using a conditional-KO mouse model in which Frataxin was
depleted in the brain [14], intraperitoneal (IP) TAT-FXN injections
showed evidence of mitochondrial localization and rescued the fatal
phenotype. TAT-FXN has also been shown to cross the blood–brain
barrier and protect dopaminergic neurons in a mouse Parkinson
disease model after IP injections [15].
Most of the mitochondrial proteins are synthesized with mito-
chondrial targeting sequence (MTS), a positively charged amphi-
pathic a-helix structure [16] typically 15–30 amino acid long,
which allows their import from the cytoplasm into the mitochon-
dria through the translocase of the outer and inner mitochondrial
membranes (TOM/TIM). Upon translocation through TOM com-
plex, the inner mitochondrial membrane potential (Dwm, negative
on matrix side) [17] and the ATP-dependent action of mitochon-
drial heat-shock protein 70 (mtHSP70) drive the protein import
into matrix space [18] where MTS is recognized by mitochondrial
processing proteases (MPP), retaining the mature protein within
the mitochondria. In this context, one of the mitochondrial pro-
teins imported into the mitochondrial matrix is HSP60, a molecu-
lar chaperone which is highly conserved from bacteria to
humans. When the importing machinery is altered, HSP60 pre-
cursor form (MTS-HSP60) accumulates and can be detected by
Western blot [19, 20]. Frataxin precursor -FXN1-210- contains an
unusual 80-amino acid-long MTS with several cleavage sites,
which undergoes two-step processing upon entry into the mito-
chondria, leading to at least a transient processing intermediate -
FXN42–210- before of an alternative processing -FXN56–210- [21]
and/or the mature form -FXN81–210- [22]. Recently, a construct
was designed (TAT-MTScs-FXN) consisting in human Frataxin
mature protein -FXN81–210- sequence coupled with TAT sequence,
that promotes cellular internalization and the mitochondrial target-
ing sequence of citrate synthase (MTScs), allowing efficient mito-
chondrial cleavage. This fusion protein was used to deliver
frataxin into mitochondria of human Bjab lymphoma cell line as
well as into cell cultures obtained from FA patients [23]. The
results showed that frataxin was delivered with higher efficiency
compared to TAT-MTScs-FXN, a construction carrying the native
MTS of human frataxin.
In this study, we have used our model of frataxin-deficient
DRG neurons [24] to show that TAT-MTScs-FXN is able to reach
mitochondria of DRG neurons, partially rescuing cell viability,
reducing neurite degeneration and decreasing a-fodrin cleavage, a
marker of apoptotic process. These neurodegenerative markers
were observed in our model as a consequence of altered calcium
homoeostasis [24]. Moreover, when TAT-MTScs-FXN was injected
in two mice models of FA [14, 25], with either 4 or 10 mg/kg,
functional frataxin was observed in muscle tissue, where it was
able to recover the activity of succinate dehydrogenase (SDH) to
the levels of heterozygous healthy mice. Reduced SDH activity
impairs mitochondrial function and has been demonstrated to
occur in Friedreich ataxia heart autopsies [10]. TAT-MTScs-FXN is
also able to promote an increase in the mean survival of mice
treated with 10 mg/kg. The results obtained with both cell and
animal models indicate that this approach can be a promising
strategy for FA treatment.
Materials and methods
Plasmids and production of lentiviral particles
Reduction in frataxin in cultured DRG neurons was achieved by
short-hairpin RNA-interfering sequences. Lentiviral vectors are routinely
produced as described in our previous publication [24]. The shRNA
lentiviral plasmids (pLKO.1-puro) for human/mouse/rat frataxin were pur-
chased from Sigma-Aldrich (Merck. Madrid. Spain). The RefSeq used was
NM_008044, which corresponds to mouse frataxin. The clones used were
TRCN0000197534, TRCN0000006137 and referred in this paper as Fxn1
and Fxn2, respectively). A non-targeted scrambled sequence (the vector
SHC002) served as a control (here referred as Scr).
Isolation and culture of DRG sensory neurons
DRGs were extracted and purified as previously described in Mincheva-
Tasheva et al., 2014 [24]. Briefly, DRGs were extracted from neonatal
rats (P3–P4) and dissociated with 0.05% trypsin (Sigma-Aldrich). Gan-
glia were mechanically disrupted with a pipette tip until obtaining a sin-
gle cell suspension in culture media supplemented with DNAse I grade
II at final concentration 3 mg/ml (Roche Diagnostics, Madrid, Spain),
which was centrifuged at 8009g r.p.m. (302 rcf) through 7,5% BSA
solution (Sigma-Aldrich) for 5 min., followed by resuspension in
enriched neurobasal culture media (Thermo Fisher Scientific—TFS,
Madrid, Spain) (NBMc) consisting of 2% horse serum (TFS), 2% B27
supplement (TFS), 0.5 mM L-glutamine (TFS), 100 U/ml penicillin plus
100 ng/ml streptomycin (TFS) and supplemented with murine b-nerve
growth factor at 50 ng/ml (PeproTech, New Jersey, USA). To prevent
growth of non-neuronal cells, culture media were supplemented with
the anti-mitotic agent Aphidicolin (Sigma-Aldrich) at final concentration
3,4 lg/ml. After 1 hr of pre-plating in a p60 tissue dish (Corning Inc.,
Fisher Scientific. Madrid. Spain) at 37°C/5%CO2, the cells were then
plated in a 24-well tissue dish (Corning Incorporated) pre-treated with
0,1 mg/ml of collagen (Sigma-Aldrich) at a cell density of 30,000 cells/
well. After 1–2 days, lentiviral transduction was performed, and len-
tivirus particles (20 ng/1000 cells) were added. After transduction,
allowed to proceed for 6 hrs, media containing lentivirus were substi-
tuted by fresh culture media. TAT-MTScs-frataxin was added to cul-
tures at 12 hrs or 48 hrs after ending lentivirus transduction protocol
and used at the concentrations indicated in each figure. Usually, con-
centrations of 1, 3 or 7 lg/ml were used. The culture medium was not
changed after the addition of TAT-MTScs-frataxin.
Immunofluorescence staining
Immunocytochemistry of DRG neurons
Cell cultures were fixed in 4% paraformaldehyde and incubated overnight
at 4°C with specific antibodies at indicated dilutions: rabbit anti-frataxin
(1:50) from Santa Cruz Biotechnology (Dallas, USA) and mouse anti-
OxPhos (1:50) from Novex (Invitrogen, Madrid, Spain)). Anti-rabbit or anti-
mouse secondary antibodies conjugated with Alexa Fluor 555 or Alexa Fluor
488 (Invitrogen, Madrid, Spain), respectively, were used at 1:300 dilutions
and incubated for 2 hrs at room temperature, protected from light. For cell
nucleus staining, the fixed cells were incubated for 5 min. with DAPI.
Micrographs were taken using an Olympus FluoView 500 (609).
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Immnunohistochemistry of heart tissue
Hearts were obtained from wild-type mice (C57BL/6J) and MCK mice
treated with vehicle or 10 mg/Kg TAT-MTScs-FXN. Unstained slides
were deparaffinized and rehydrated. Heat-induced epitope retrieval was
performed with Diva antigen retrieval buffer (Biocare Medical Pacheco,
CA, USA). Following a rinse, a protein blocking step was performed with
Sniper protein block (Biocare Medical). Slides were again rinsed and
anti-frataxin antibody, ab175402 from Abcam (Cambridge, UK), was
applied at 1:50 dilution for 60 min. Slides were rinsed. Endogenous per-
oxidase was blocked using Peroxidase 1 [Biocare Medical]. After a
rinse, the secondary antibody, biotinylated goat anti-rabbit IgG (1:500
dilution) from Jackson Immunoresearch (ref 111-065-144) was applied
for 30 min. The slides were rinsed, and ABC Elite was added for
30 min., followed by another rinse. Colour development was achieved
by adding Sigma Fast DAB solution for 5 min. Slides were rinsed, coun-
terstained with haematoxylin and coverslipped. All rinse steps were per-
formed with TBS-Autowash (Biocare Medical).
Survival and neurite degeneration analyses
Neuronal survival was measured with a 916 lens and cross-marked
wells as described [24]. Neurons at zero and 5 days were counted at
four fields per cross-marked well, using three wells per condition
tested. Experiments were repeated at least three times. Neurite degener-
ation was measured with a 932 lens and a grid, which was created
over each image with NIH Image J with the grid plugin (Image size
680 9 512 and line area 10,000 pixels2). Healthy and degenerated neu-
rites (displaying neurofilament aggregates) were counted at three grid
fields per image and three images per well were analysed. For each
condition, we used three different wells. Experiments were repeated at
least three times.
Animal care
All experiments were conducted in accordance with the protocols
described by the National Institutes of Health’s Guide for the Care and
Use of Animals and were approved by JAX institutional animal care and
use committees. Mice were ear notched for identification and housed in
individually and positively ventilated polycarbonate cages with HEPA-fil-
tered air at a density no greater than of four to five mice per cage. Pine
shaving-based corn cob bedding was used, and cages were changed
every 2 weeks. The animal room was lighted entirely with artificial fluo-
rescent lighting, with a controlled 12-hrs light/dark cycle (7 a.m. to 7
p.m. light). The normal temperature and relative humidity ranges in the
animal rooms were 22  4°C and 50  15%, respectively. The animal
rooms were set to have 15 air exchanges per hour. Filtered tap
water, acidified to a pH of 2.8–3.2 and LabDiet 5LL4 were provided
ad libitum.
Animals breeding and genotyping
FA-KO mouse model (B6.Cg-Tg. (Fxn)1 Sars FXN tm1mkn/J, Jax stock
#18299): Mice are homozygous to the mouse Frataxin gene knockout
and hemizygous to the human FA-related Frataxin gene, containing 500
GAA trinucleotide repeats. Mice, licensed and routinely bred at the
Jackson laboratory, were produced by crossing heterozygous Frataxin
KO mice with mice heterozygous for the Frataxin KO and hemizygous
human FA-related Frataxin gene. This model is characterized by a low
human Frataxin expression level, showing normal behavioural, biochem-
ical or histological measures [25].
FA-Conditional-KO mouse model (Mutant Mck-Cre-FxnL3/L, Jax Cus-
tom Breeding stock 371001): Mice, licensed to Bioblast Pharma, carrying
the floxed Frataxin allele, were generated at the laboratory of Koeing and
Puccio as described [14]. Sperm from two male mice were used for IVF
with inbred C57BL/6J (JAX Stock No: 000664) as oocyte donors, per-
formed with The Jackson Laboratory common procedures. Two Jax
stocks (Stock 006475 B6.FVB(129S4)-Tg(Ckmm-cre)5Khn/J and Stock
16842 B6.Cg-Fxntm1Mkn/J) were used for breeding as described below.
Mutant animals (compound heterozygotes at the murine Frataxin
locus harbouring the floxed allele Fxntm2Mkn and the null allele Fxnt-
m1Mkn and carrying the Tg (Ckmm-cre) 5Khn) were generated by inter-
crossing animals homozygous for the floxed allele Fxntm2Mkn with
animals heterozygous for the null allele Fxntm1Mkn and hemizygous for
the Tg (Ckmm-cre) 5Khn transgene. Mutants were identified by PCR
genotyping of genomic DNA isolated from tail biopsies. To genotype the
Fxntm1Mkn targeted mutation, multiplexed PCR was performed on DNA
isolated from tail biopsies using the following primers: Common-F: 50-
CTG TTT ACC ATG GCT GAG ATC TC-30; WT-R: 50-CCA AGG ATA TAA
CAG ACA CCA TT-30; MUT-R: 50-CGC CTC CCC TAC CCG GTA GAA TTC-
30 generating at 245-bp mutant product and 499-bp wild-type product.
To identify animals harbouring the floxed allele, the following primer
sets were used: FxnflF: 50-GGTCCATATAGTGCGTTCCAG-30 and FxnflR:
50-CGCTCTCTTCAGAC AGACCA-30 generating a 300-bp mutant product
and a 256-bp wild-type product. Animals harbouring the Tg(Ckmm-cre)
5Khn transgene were identified with the primer set: Ckmm-F: 50-
GTGAAACAGCATTGCTGTCACTT-30 and Ckmm-R: 50-TAAGTCTGAACCCG
GTCTGC-30 generating a 450-bp mutant product. According to a recent
paper [26] (Perdomini, 2014), mutant Mck-Cre-FxnL3/L mice are
asymptomatic at wean and exhibit weight loss and die of progressive
cardiac failure at 65  10 days of age.
Administration of TAT-MTScs-frataxin to mice
and survival monitoring
Treatment was initiated at time of weaning (at 3–4 weeks of age). Mice
were intravenously (IV) injected twice weekly (at least 3 days apart)
with either vehicle (containing 50 mM Tris-HCl, 300 mM NaCl, 10%
glycerol pH 8), or with TAT-MTScs-FXN at doses of 4 mg/kg or 10 mg/
kg.
For survival experiments, treatment was initiated at time of weaning
(3–4 weeks of age). MCK mice were intraperitoneally (IP) injected twice
weekly following the protocol described above. MCK mice survival was
monitored daily. Additionally, mice that lost >15% weekly weight were
killed and registered as death incidents. Significance was defined using
log-rank (Mantel–Cox) test.
Isolation of mitochondria from muscle tissue
Mice tissue was extracted, and the mitochondrial fraction was isolated
using mitochondria isolation kit (Abcam, ab110168) according to the
manufacturer’s protocol. Mitochondrial pellets were preserved at
80°C.
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Measurement of frataxin amounts in muscle
mitochondrial fractions
Human frataxin level was analysed in isolated mitochondrial fractions
using Abcam ab176112 ELISA kit, according to the manufacturer’s
instructions.
Mitochondrial complex II activity assay
Complex II activity (succinate dehydrogenase, or SDH) in mitochondrial
fractions was determined using a commercially available kit (BioVision,
K660-100, Milpitas, California, USA) according to manufacturer’s instruc-
tions. Mitochondrial pellets were resuspended with 90–150 ll succinate
dehydrogenase (SDH) buffer, according to mitochondrial pellet amount
(0.2V of resuspended volume) was used in duplicates. Protein was deter-
mined by the Bradford assay. Enzyme activity was followed at 600 nm
and measured every 2 min. up to 20 min. Specific activity was given as
DOD per mg of protein.
Western blot analysis
Western blot analysis were performed using equal volumes of mito-
chondrial extracts, diluted in sample buffer, separated using 4–12%
gradient SDS-PAGE gels. External human Frataxin protein was used as
a positive control (5 lg/well). COX-IV mitochondrial marker was
detected using specific antibody from R&D Systems Abingdon, UK
(MAB6980) diluted 1:1000 in blocking buffer at room temperature for
1.5 hrs. Following analysis, nitrocellulose membranes were washed,
striped and subjected to Frataxin detection, using Frataxin antibody
from Abnova, Walnut, CA, USA (H00002395-M02). Both Frataxin and
COX-IV signals were quantified using Image J software, and Frataxin
signal was normalized to COX-IV signal. For DRGs, cells were rinsed
three times in ice-cold PBS (pH 7.4) and lysed with 2% SDS,
125 mM Tris and protease inhibitors (Roche) to obtain crude extracts
used for SDS–polyacrylamide gel electrophoresis. In Western blot anal-
ysis, PVDF membranes were used for HSP60, fodrin, procaspase 9
and actin detection and nitrocellulose membranes for Frataxin detec-
tion. Monoclonal antibody against HSP60 was from Acris-Origene
Technology Rockville, MD, USA (TA326374) used at 1/6000 dilution;
a-fodrin cleavage products antibody was from ENZO Life Sciences
(Farmingdale, NY, USA) used at 1:1000 dilution, and anti-caspase 9
monoclonal antibody was from Cell Signaling Technology (9508) used
at 1:1000 dilution. Frataxin was detected using anti-Frataxin antibody
from Santa Cruz Biotechnology 1:250 dilution. Fodrin, HSP60, procas-
pase 9 and frataxin signals were normalized to actin signal, using anti-
b-actin antibody from Chemicon-EMD Millipore, Madrid, Spain at
1:50,000 dilution.
Data analysis
The data obtained from at least three independent experiments were
used for statistical analyses. Values were expressed as mean 
S.E.M. (error bars). One-way ANOVA was used to assess survival, neu-
rite degeneration between groups. If the ANOVA test was statistically
significant, we performed post hoc pairwise comparisons using the
Bonferroni test. The P-values lower than 0.05(∗), 0.01(∗∗) or 0.001
(∗∗∗) were considered significant. For in vivo studies, statistical anal-
yses were performed using Statistical Package for the Social
Sciences (SPSS software version 22. licence number f11340ae0
8e3b46186e4).
Results
TAT-MTScs-FXN penetrates DRG neurons
TAT-fusion proteins have been used to successfully deliver pro-
teins and peptides into cells as treatment for various diseases.
Although the mechanism is unknown, transduction mechanism
requires an initial ionic interaction between TAT peptide and the
cell surface, followed by TAT-fusion protein internalization through
lipid-raft-dependent micropinocytosis [27]. Using our model of rat
primary culture, we tested the ability of the TAT-MTScs-FXN to
penetrate frataxin-deficient DRG neurons. DRG neurons were
transduced with lentiviruses carrying either Fxn1 or Fxn2 shRNAs
to reduce the endogenous expression level of frataxin or len-
tivirus carrying Scr shRNA to use it as control condition for fra-
taxin level. Efficient reduction in endogenous levels of frataxin
was achieved by Fxn1 and Fxn2 interference RNAs (shown in
Fig. S1). After 48 hrs of lentiviral transduction, TAT-MTScs-FXN
(7 lg/ml) or vehicle solution was added to cultures. To evaluate
the presence and mitochondrial location of frataxin in these cells,
cultures were co-stained by immunofluorescence with anti-frataxin
and anti-OxPhos antibodies. The latter being a cocktail of anti-
bodies that recognize different subunits of the mitochondrial res-
piratory chain. Frataxin is almost undetectable in frataxin-depleted
DRG neurons (data not shown). In contrast, frataxin can be
detected after TAT-MTScs-FXN treatment, indicating that the
fusion protein is able to penetrate frataxin-deficient cells (Fig. 1).
Moreover, the punctate pattern of frataxin staining in the cell
soma and along the neurites mostly co-localize with mitochon-
drial marker, which shows that TAT-MTScs-FXN is targeted to
the mitochondria.
TAT-MTScs-FXN processing in DRG neurons
The results in Figure 1 indicate that frataxin reach mitochondria.
To ensure that TAT-MTScs-FXN is correctly processed by DRG
neurons, cells were taken at day 5, lysed and protein samples
analysed by Western blot to evaluate frataxin levels. The frataxin
signal in TAT-MTScs-FXN-treated DRG cultures is shown in
Figure 2 where the full length, intermediate and mature forms can
be detected. It is worth noting that in Fxn1 and Fxn2 cultures the
levels of unprocessed construct were higher than those exhibited
Scr cultures, suggesting a reduced ability to process frataxin. This
could be a consequence of the fact that, as we previously
reported [24], frataxin-depleted neurons display decreased mito-
chondrial membrane potential (Dwm) that could potentially affect
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TAT-MTScs-FXN penetration into the mitochondria. Indeed, Fxn1
and Fxn2 cultures displayed higher amounts of whole fusion pro-
tein and intermediate forms compared to control cultures (Scr) for
each dose used (Fig. S2A and B). Interestingly, the level of
mature FXN form in TAT-MTScs-FXN-treated Fxn1 and Fxn2 cul-
tures is not inferior to the level in Scr culture as one could expect
(Fig. 2B).
HSP60-deficient processing is reversed by TAT-
MTScs-FXN
Impairment of the frataxin construct processing described above
prompted us to analyse whether this was only affecting TAT-MTScs-
FXN fusion protein or could also affect other mitochondrial proteins.
DAPI/OxPhos DAPI/FXN Merge
Fig. 1 TAT-MTScs-FXN penetrates DRG neurons. Immunofluorescent staining for frataxin (red) and OxPhos (green) in DRG neurons (Fxn2) treated
with 7 lg/ml TAT-MTScs-FXN 12 hrs after lentiviral transduction. Images were obtained after 5 days of culture. OxPhos staining was used to visual-
ize mitochondria. Nuclei were stained with DAPI.
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Fig. 2Western blotting of TAT-MTScs-FXN
processing. (A) Cells from Scr, Fxn1 and
Fxn2 treated with 7 lg/ml TAT-MTScs-
FXN 12 hrs after lentiviral transduction
were lysed after 5 days of culture and
blotted to detect frataxin levels (b-actin
was used for normalization). Results indi-
cate penetration and processing of TAT-
MTScs-FXN in all cultures. Differences in
intermediate forms are evident in Fxn1
and Fxn2 compared to control (Scr) con-
ditions. The lane on the right is to show
the molecular weight of the intact TAT-
MTScs-frataxin form. Lane M indicates
the position of the molecular weight mar-
ker of 25 kD. (B) The histogram illustrates
the relative amounts of frataxin forms
when TAT-MTScs-frataxin (7 lg/ml) was
added to the cultures 12 hrs after len-
tivirus withdrawal. Error bars represent
mean  S.E.M., n = 4.
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For this reason, we analyse the HSP60, a mitochondrial molecular
chaperone involved in protein folding, acting after the mitochondrial
import machinery [28, 29]. As HSP60 is targeted to mitochondria, it
should also be processed to reach the mitochondrial matrix [30].
Figure 3 (lanes 1–3) shows that in Fxn1 and Fxn2 cells, the precursor
form (p) is increased with respect to control cultures (Scr), and
accordingly, mature (m) form is decreased. As this could be a direct
consequence of low frataxin levels displayed in Fxn1 an Fxn2 cultures,
we tested the effect of adding TAT-MTScs-FXN to these cultures. As
shown in Figure 3 (lanes 4–6), the levels of precursor and mature
forms displayed in Fxn1 and Fxn2 are as those present in control Scr
cultures, indicating that the mature frataxin form generated in Fxn1
and Fxn2 by TAT-MTScs-frataxin was sufficient to revert the anoma-
lous processing of the molecular chaperone.
Fodrin cleavage is reduced by TAT-MTScs-FXN
The ability of TAT-MTScs-FXN to restore mitochondrial fitness to
improve HSP60 processing leads us to analyse the reduction in apop-
totic markers. In a previous study, we reported that apoptotic markers
such as caspase 3 activation or a-fodrin cleavage were clearly
observed [24]. In response to intracellular free Ca2+ increase, calpain
and caspase proteases are activated, and among others, they cleave
a-fodrin, a cytoskeletal protein of 280 kD, rendering protease-specific
breakdown products (SBDPs) [31]. Both proteases cleave the
a-fodrin to produce a non-specific 150-kD breakdown fragment
(SBDP150), and then, a second cleavage results in a calpain or cas-
pase 3-specific product of 145 (SBDP145) or 120 kD (SBDP120),
respectively. The presence of SBDP120 is considered a marker of
apoptotic process [32]. Based on these results, we evaluated the ther-
apeutic effect of TAT-MTScs-FXN on frataxin-deficient DRG neurons.
Treating Scr and Fxn cultures with different doses of TAT-MTScs-FXN
(1, 3 and 7 lg/ml) or vehicle solution at different time-points (48 and
12 hrs after lentiviral transduction), we observed that TAT-MTScs-
FXN concentrations reduced a-fodrin cleavage in a dose-dependent
manner (Fig. 4A). A histogram showing such decrease in each culture
is presented in Figure 4B. Also, addition of TAT-MTScs-FXN has a
higher impact on reduction in fodrin cleavage when added shortly
after lentivirus transduction. As shown in Figure 4C and D, addition of
TAT-MTScs-FXN 7 lg/ml at 12 hrs after lentiviral transduction pro-
motes optimal decrease in SBDPs as compared with results obtained
by adding TAT-MTScs-FXN at 48 hrs. These results are also in agree-
ment with those obtained by analysing caspase 9 activation, a marker
of intrinsic or mitochondrial apoptotic pathway (for a review see
[33]). In Figure 4E and F, reduced levels of the precursor form are
observed in Fxn1 and Fxn2 cells, indicative of cleavage (activation) of
this caspase. When treated with TAT-MTScs-FXN, these cells display
caspase 9 amounts similar to those observed in Scr cultures. These
results show that apoptotic traits are reduced by TAT-MTScs-FXN
and, consequently, degeneration of frataxin-deficient DRG neurons
should be prevented.
Neurite degeneration and neuronal death are
reduced by TAT-MTScs-FXN
Frataxin depletion in DRG neurons promotes apoptosis and neurite
degeneration, indicated by loss of mitochondrial membrane potential
and formation of neurofilament aggregates [24]. To further evaluate
the positive effects of TAT-MTScs-FXN on frataxin-deficient DRG neu-
rons, neurite degeneration was analysed in our cultures. As shown in
Figure 5A, addition of TAT-MTScs-FXN (7 lg/ml, 12 hrs after lentivi-
ral transduction) to Fxn1 and Fxn2 cultures reduced neurofilament
aggregates in neurites by 50% in Fxn1 and 35% in Fxn2. Images are
shown in Figure 5B where aggregates are marked with arrows. In Fig-
ure 5C, we show that neurite degeneration is reduced in a concentra-
tion-dependent manner, with 1, 3 and 7 lg/ml treatment after 48 hrs
of transduction. Control Scr cultures were not affected by TAT-
MTScs-FXN treatment (Fig. 5B, panels on the left). Besides neurite
degeneration, Fxn1 and Fxn2 cultures showed a drastic decreased
survival in accordance with increased apoptosis [24]. For this reason,
we analysed the ability of TAT-MTScs-FXN to recover survival in fra-
taxin-deficient DRG neurons. As shown in Figure 6A and B, addition
of TAT-MTScs-FXN to Fxn1 and Fxn2 cultures after 12 hrs of lentiviral
transduction resulted in a significant decrease in the percentage of
mortality. At day 5, these cultures showed an increased survival rate
of 16.6% and 14.6% per cent, respectively. When the compound was
added 48 hrs after lentivirus transduction (Fig. 6C), the compound
was still able to rescue the cultures from cell death although, com-
pared to values achieved with TAT-MTScs-FXN added at 12 hrs, sur-
vival increased to a lesser extent (14.9% and 11.4% for 7 lg/ml and
9.2% and 6.8% for 3 lg/ml, in Fxn1 and Fxn2, respectively). Treat-
ment with 1 lg/ml did not show any significant effect on cell survival.
From these results, it can be concluded that in cultured frataxin-
deficient DRG neurons, TAT-MTScs-FXN is able to reduce neurite
degeneration and, consequently, increase survival.
Organ penetration, mitochondrial localization of
TAT-MTScs-Frataxin in FXN-KIKO mouse model
To test whether TAT-MTScs-FXN was also able to reach mitochon-
dria in vivo, we used two mice models developed to study FA.
50
75
TAT-MTScs-FXN
(7 μg/ml)
Hsp60p
m
Scr Fxn1 Fxn2 Scr Fxn1 Fxn2
Mw
(kDa)
1 2 3 4 5 6
Fig. 3 HSP60 processing in frataxin-deficient neurons. Western blot
detection of HSP60 precursor (p) and mature (m) forms in crude
extracts from Scr, Fxn1 and Fxn2 cells after 5 days of culture without
treatment (lanes 1–3) or treated with TAT-MTScs-frataxin at 7 lg/ml
(lanes 4–6). Mw markers are indicated. Note that precursor form
increases in untreated Fxn1 and Fxn2 cultures and the processing is
restored by TAT-MTScs-FXN addition.
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For organ penetration and mitochondrial localization studies, mice
model, described by Sarsero et al. [25], was IV injected with TAT-
MTScs-FXN twice a week at 10 mg/kg dose, followed by 2 weeks
of washout period (Fig. 7A). Mitochondrial fractions were obtained
from muscles harvested at each time-point. As can be seen
(Fig. 7B), muscle Frataxin levels in mitochondria increased one
week after study initiation, reaching highly significant level after
three weeks of drug administration in comparison with untreated
mice. The values show a significant increase of more than three-
fold compared to untreated mice that show values around 550 pg/
mg. It is worth mentioning that the maximum values achieved of
1500 pg/mg of total protein at 21 days, represents around 15%
of the normal values (i.e. concentration is typically around
10,300 pg/mg of total protein in muscles of healthy animals—data
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Fig. 4 Fodrin cleavage is reduced by TAT-MTScs-FXN treatment (A) Western blotting of a-Fodrin fragmentation. Crude extracts from Scr, Fxn1 and
Fxn2 cells treated with increasing doses of 1, 3 and 7 lg/ml TAT-MTScs-FXN or vehicle solution 48 hrs after lentiviral transduction were checked
for a-Fodrin fragmentation (b-actin was used for normalization). TAT-MTScs-FXN caused reduction in a-fodrin cleavage as judged by the decrease
of fodrin fragments (150 and 120 kD) in a dose-dependent manner. (B) Histogram showing the decrease in relative amounts of fragmented a-fodrin
shown in A as function of the amount of TAT-MTScs-FXN added to cultures. (C) a-fodrin cleavage after 5 days analysed in Scr, Fxn1 and Fxn2 cells
treated with 7 lg/ml TAT-MTScs-FXN or vehicle solution 12 or 48 hrs after lentiviral transduction. The histogram in (D) represents the values of
fodrin fragments shown in (C) to illustrate the differences of adding the compound at 12 or 48 hrs. Values are referred to untreated control (Scr)
culture. In (E), procaspase 9 levels are shown in Scr, Fxn1, Fxn2 treated with TAT-MTScs-FXN and untreated. Note that the decreased amounts in
untreated Fxn1 and Fxn2 are re-established by TAT-MTScs-FXN addition. The histogram in (F) represents the values shown in (E). Asterisks (*)
show significant values compared with control conditions (Scr); bars with # indicate significant differences with respect to the corresponding
untreated control culture. Error bars represent mean  S.E.M. In all figures, N is at least n = 4.
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not shown). Interestingly, during the washout period, 2 weeks
after ceasing administration, the frataxin levels were reduced but
still remained significantly above (around twofold) compared to
those of untreated mice. Besides to evaluate the increase of fra-
taxin amounts in tissues other than muscle, brains from treated
and control animals were used and shown in Figure S3.
Mitochondrial functions restored with
TAT-MTScs-Frataxin
The KIKO-FA model described above, provided that frataxin is reaching
mitochondria, should display an improved phenotype. Hence, to exam-
ine frataxin function in the mitochondria, we used the MCK-conditional
mouse model [14] because striated muscle tissue is depleted of
frataxin. As shown in Figure 8A, processed frataxin is clearly observed
in muscle mitochondrial fractions obtained from mice treated with
TAT-MTScs-FXN. For comparison, a mitochondrial protein, CoxIV, was
used as internal standard. The presence of frataxin in muscle was
dose-dependent as, as shown in Figure 8B, animals treated with
10 mg/kg showed higher amounts (around threefold increase) com-
pared to those treated with 4 mg/kg. To examine the ability of this fra-
taxin to restore mitochondrial functions, the activity of succinate
dehydrogenase (complex II) was tested. This is of special interest
because deficiencies in succinate dehydrogenase have been associated
with FA [10] and late-onset neurodegeneration characterized by pro-
gressive optic atrophy, ataxia and myopathy [34]. As shown in Fig. 8C,
the enzymatic activity of SDH was increased, using either 4 mg/kg or
10 mg/kg, when compared to vehicle-treated mice and restored the
enzymatic activity values to those exhibited by heterozygous healthy
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mice (dashed line), thus indicating that the amount of frataxin in mus-
cle is sufficient to partially restore mitochondrial functions.
Survival of MCK mice treated with TAT-MTScs-
FXN
To test whether TAT-MTScs-FXN was able to rescue MCK pheno-
type, mouse survival was analysed as described in Materials and
methods. Using intravenous route (IV) of injection, we did not
observe a significant increased survival (Fig. S4). The reason for this
could rely on the fact that when IV was used, amounts of frataxin in
heart mitochondria of treated animals did not vary substantially
when compared to controls (Fig. S5). MCK phenotype is mainly
related to cardiac disfunctions. Firstly, we tested different ways of
administration to deliver TAT-MTScs-FXN to heart tissue. Intraperi-
toneal injections resulted in an improvement compared to SC, IM
and IV (Fig. S5). To test the presence of frataxin in cardiomyocytes,
we performed immunohistochemistry on heart tissue treated with
vehicle or TAT-MTScs-FXN. As shown in Figure 9, frataxin was
undetectable in vehicle-treated MCK mice while wild-type mice and
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Fig. 5 Neurite degeneration is reduced by
TAT-MTScs-FXN treatment. (A) Histogram
showing the significant decreased percent-
age of neurite degeneration (measured as
described in Materials and methods) pro-
duced by TAT-MTScs-FXN treatment using
7 lg/ml after 12 hrs compared to
untreated cells. Error bars represent
mean  S.D., n = 4. (B) Representative
images of 5-day cultures of Scr, Fxn1 and
Fxn2 treated with 7 lg/ml TAT-MTScs-
FXN or vehicle solution 12 hrs after len-
tiviral transduction. Note the decrease in
neurite aggregates (indicated by arrows)
in treated cells (lower panels) compared
with untreated cultures (upper panels). (C)
Histogram showing the significant
decreased percentage of neurite degenera-
tion (measured as described in Materials
and methods) produced by TAT-MTScs-
FXN treatment (using 1 lg/ml, 3 lg/ml
and 7 lg/ml) compared to untreated cells.
Error bars represent mean  S.D., n = 4.
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TAT-MTScs-FXN-treated MCK mice show accumulation of frataxin
near intercalated discs of cardiomyocytes. Indeed, mitochondria
have been shown to be associated with intercalated discs in car-
diomyocytes [35]. Moreover, the disorganization of the muscle
fibres of MCK mice, a key trait of the model [36], was partially
restored with 10 mg/kg TAT-MTScs-FXN treatment.
Then, for survival assays, MCK mice were treated with IP
injections of 4 mg/kg or 10 mg/kg. Although at 4 mg/kg they did
not show significant differences with respect to vehicle (not
shown), treatment with 10 mg/kg (Fig. 10A) shows an increase in
total lifespan. The increased lifespan become evident in the inter-
val from 65 to 75 days, where the maximum differences were
observed. The mean survival was significantly higher for treated
mice compared to control mice (67 versus 71 days, respectively).
Moreover, in Figure 10B, age of death distribution is shown and
the beneficial effects of the treatment are evident for the great
majority of mice.
Discussion
Frataxin depletion is the main cause of Friedreich ataxia. To date,
there are no cures available and many efforts are currently made to
develop a treatment for this disease (for an updated review of the
different therapeutic approaches see curefa.org/pipeline). One of the
strategies consists in replacing frataxin by an exogenous source as
TAT-based carrier molecule: TAT-FXN. This technology allows cell
penetration and mitochondria localization of exogenous FXN in FA
mice model in vivo and in cell derived from FA patients [13, 15].
Recently, TAT-MTScs-FXN was shown to be more efficient than
TAT-MTSfxn-FXN in mitochondria localization [23]. Pioneering stud-
ies conducted at Payne’s laboratory showed that TAT-frataxin fusion
protein can deliver frataxin to mitochondria and increase lifespan of
animal models of the disease by 53% [11]. In this study, we used
TAT-FXN-based construct in a neuronal model of the disease and
show that TAT-MTScs-FXN was able to penetrate frataxin-deficient
sensory neurons and display a mitochondrial staining pattern. The
amount of mature frataxin in TAT-MTScs-FXN-treated Fxn1 and
Fxn2 neurons was greatly increased compared to vehicle. Using
mouse models, we also showed that mitochondria isolated from
treated mice display detectable amounts of the protein. The use of
frataxin-deficient neuronal and muscle tissues enabled us to exam-
ine whether alterations in TAT-MTScs-FXN processing occur. In
DRG neurons, we observed an alteration in TAT-MTScs-FXN
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Fig. 6 Cell survival is enhanced by TAT-MTScs-FXN treatment. (A)
shows the percentage of surviving DRG neurons at day 5 of cultures
treated with TAT-MTScs-FXN (7 lg/ml, 12 hrs post-lentivirus transduc-
tion) compared to untreated cells. Note the significant survival increase
by TAT-MTScs-FXN supplementation in both Fxn1 and Fxn2 cultures.
Error bars represent mean  S.D., n = 4, and a range of 956–1184
neurons was scored for Scr conditions and 1397–1733 for each Fxn1
and Fxn2 conditions. (B) Representative images of neuronal survival
with or without treatment (corresponding to 1/4th of full-size field).
Images were taken at the same fields of cultures at day 0 and day 5.
Arrows indicate the neuronal bodies present at day 0 and absent at day
5. In (C), the effect on survival of DRG-deficient neurons when treated
with TAT-MTScs-FXN added at 48 hrs after lentivirus transduction is
shown. Significance is marked as (*) when referred to no treatment in
Scr cultures and (#) when comparing 1, 3 and 7 lg/ml treatments.
Error bars represent mean  S.D., n = 4, a range of 436–1233 neurons
were scored for Scr condition and 867–1832 for each Fxn1 and Fxn2
conditions.
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processing. In Fxn1- and Fxn2-treated neurons, we observed an
accumulation of unprocessed TAT-MTScs-FXN, and intermediate
forms, compared to Scr neurons treated with the same amount of
TAT-MTScs-FXN but not mature form. This apparent contradiction
can be explained by the results reported by Nabhan et al. 2015. The
study demonstrated that CCCP treatment, which reduce Dwm, of
293T cells, increased precursor form but not mature form which
remains unaltered [37]). Our findings would be in agreement with
these results. In muscle samples obtained from mice models, we
did not observe any accumulation of TAT-MTScs-FXN, suggesting
that it is mostly processed. One can hypothesize that impairment in
protein processing is due to altered mitochondrial functions induced
by frataxin deficiency, including the decreases in mitochondrial
membrane potential (Dwm) and considering that mitochondrial alter-
ations are probably stronger in frataxin-deficient neurons than in fra-
taxin-deficient muscle cell. As Dwm is a critical hub for the
efficiency of mitochondrial protein import [17] and matrix protein
translocation additionally requires ATP for mtHSP70 activity [18],
major TAT-MTScs-FXN accumulation in frataxin-depleted DRG neu-
rons than in Scr neurons could be explained by the shift of mito-
chondrial energetic state and the quality of mitochondria, as protein
import activity can act for sensing mitochondrial fitness [38]. For
this reason, we explore whether it was a condition specifically
related to the nature of the construct or other mitochondrial proteins
can suffer such impairment. For this reason, we selected HSP60, a
molecular chaperone that must be imported and processed to reach
the mitochondrial matrix. As shown in Figure 3, HSP60 processing
is clearly impaired in Fxn1 and more clearly in Fxn2. The difference
between both cultures can be attributable to lower levels of frataxin
in Fxn2 cultures (as shown in Fig. S1). HSP60 impaired processing
was not reported yet in frataxin-deficient cells, and it could be
relevant for the disease. In this context, it is worth mentioning that,
beyond its function assisting polypeptides to fold properly once
imported into the mitochondria, defects affecting its molecular chap-
erone activity have been related to neurodegenerative diseases such
as spastic paraplegia [39, 40, 41] or the MitCHAP 60 disease [42,
43]. The impact that such deficiency could have in frataxin-depleted
cells remains to be explored.
Concerning other neurodegenerative markers, we previously
described [24] that frataxin-deficient cells DRG neurons showed
decreased Dwm and apoptotic traits such as increased neurite degen-
eration and a-fodrin cleavage. The fragmentation of this structural
protein has been observed in normal ageing [44] and neurodegenera-
tive diseases such as Alzheimer disease [45]. The results presented
here show that TAT-MTScs-FXN was able to reduce a-fodrin cleav-
age, neurite degeneration and cell death in a dose-dependent manner.
Also, when administered at 12 hrs after transduction, a-fodrin cleav-
age is more efficiently reduced than when added at 48 hrs (Fig. 4C
and D). Rescuing from apoptotic process is reasonably more difficult
at 48 hrs than after 12 hrs. Indeed, a-fodrin cleavage is produced by
caspase 3 and calpain proteases, which become activated by altered
calcium homoeostasis through activation of Bax, a pro-apoptotic pro-
tein [46, 47]. Fodrin cleavage summarizes the activation of pro-apop-
totic pathway involving proteins such as P-CREB, BAX, and others
[48] with the participation of altered levels of calcium. Reduction in
this fragmentation implies a reduction in pro-apoptotic factors and
restoring calcium homoeostasis. Then, it is reasonable that reduction
in a-fodrin cleavage—as shown in Figure 4A and B—and increase in
procaspase 9 (Fig. 4E and F) are both due to restoring frataxin levels.
These results agree with decreased neurite degeneration (Fig. 5) and
with the increased survival observed by supplementing the cultures
with TAT-MTScs-FXN at several doses (Fig. 6).
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Fig. 8 TAT-MTScs-FXN is processed and functional in mice muscle (A) A representative image of frataxin present in mitochondrial fractions obtained
from mice treated for 3 weeks—twice a week—with 10 mg/kg TAT-MTScs-FXN (lanes 1–6) or vehicle (lanes 7–8 where frataxin is almost unde-
tectable). The same protocol was executed by administrating 4 mg/kg (not shown). Each lane (1–6) represents individual mouse. Unprocessed
external TAT-MTScs-FXN protein was run in parallel (lane 9). Lower panel shows the levels of COX-IV that was used as internal mitochondrial mar-
ker. The frataxin levels normalized against COX-IV are shown in (B). Dashed line indicates the frataxin levels of heterozygous, healthy mice. Bars
represent mean  S.E.M., n = 4. In (C), the activity of mitochondrial complex II (succinate dehydrogenase) is shown. Values were obtained in sam-
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P < 0.05,ANOVA).
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Fig. 9 Frataxin detection in cardiac tissue of MCK mice model. Immunohistochemical staining of frataxin from WT, MCK vehicle-treated and MCK
TAT-MTScs-FXN-treated mice are shown. Arrows indicate Frataxin accumulation near intercalated discs of cardiomyocytes for WT and MCK TAT-
MTScs-FXN-treated mice, but no frataxin were detected in MCK vehicle-treated mice.
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Conditional mice models of the disease used in this study showed
alterations in both aconitase activity and mitochondrial electron trans-
port chain [14], thus compromising mitochondrial energy production.
We showed here that mice injected with TAT-MTScs-FXN reaches the
muscle mitochondria achieving 15% of the values displayed by
healthy animals. Although the increase in these values is moderate,
they showed to be able to restore succinate dehydrogenase activity
(Fig. 8C). Concerning animal survival, although the differences in
mean survival treated with 4 mg/kg were not significant, treatment
with 10 mg/kg proved to be partially efficient as the mean survival
showed a slight but significant increase, mainly in the interval of 60–
70 days. Moreover, the age of death was significantly increased with
10 mg/kg treatment.
FA is characterized by gradual neurodegeneration that precedes
fatal cardiac condition. Unfortunately, there is no suitable neuronal
model that mimics neurodegeneration and allows screening for drugs
efficiency. In this paper, we show the ability of TAT-MTScs-FXN to
protect neurodegeneration of primary neurons that are frataxin-
depleted. These “in vitro” results combined with the data provided by
tests performed “in vivo” using mice models of Friedreich ataxia sug-
gest that TAT-MTScs-frataxin can be considered a candidate for the
disease therapy.
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Figure S1 Frataxin levels in Scr, Fxn1 and Fxn2 after lentivirus trans-
duction. Levels of frataxin were analysed by Western blotting in con-
trol (Scr) and frataxin-depleted neurons (Fxn1 and Fxn2). Actin was
used as a control of protein loading.
Figure S2 Relative amounts of full length, processed (interme-
diate and mature) TAT-MTScs-frataxin forms. (A) The amounts
of the frataxin forms were evaluated in Scr, Fxn1 and Fxn2 cul-
tures after addition of TAT-MTScs-frataxin at 1, 3 or 7 lg/ml
(as indicated) to each culture, 48 hrs after lentivirus transduc-
tion. Error bars represent mean  S.E.M., n = 4 (B) Endoge-
nous frataxin levels compared to treated cells. Cells from Scr,
Fxn1 and Fxn2 untreated and treated with 1 and 7 lg/ml TAT-
MTScs-FXN 48 hrs after lentiviral transduction were lysed after
5 days of culture and blotted to detect frataxin levels (b-actin
was used for normalization). Note the increase in mature fra-
taxin levels in treated cells compared to untreated cells.
Figure S3 Increased frataxin in brain samples (Sarsero model). Brain
tissue samples were assayed for frataxin amounts using ELISA test.
Treatment was initiated at 6–8 weeks of age. Mice were intravenously
injected twice a week with vehicle or TAT-MTScs-frataxin at 4 mg/kg.
Values are expressed as pg/mg of whole tissue extract. N = 3 for
each condition.
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Fig. 10 Survival of TAT-MTScs-Frataxin-treated MCK mice. (A) Kaplan–
Meier curve generated by GraphPad Prism showing the lifespan
increase in MCK-conditional mouse model treated with TAT-MTScs-FXN,
P = 0.0162 using log-rank (Mantel–Cox) test. (B) Age of death, average
was calculated using Gehan–Breslow–Wilcoxon test generated by
GraphPad Prism, P = 0.0251. Mice treated with 10 mg/kg of TAT-
MTScs-FXN or vehicle (IP injection) were tested for survival (as
described in Materials and methods). N = 11 for each group.
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Figure S4 Per cent of survival by administrating TAT-MTScs-frataxin
intravenously. Survival of mice treated with vehicle or with TAT-
MTScs-frataxin at 10 mg/Kg was followed (see Materials and meth-
ods). For controls, 5 animals were used and 10 animals for treatment.
Note that no significant differences were observed in neither in mean
nor in total lifespan. N = 5 for vehicle and N = 10 for TAT-MTScs-
FXN.
Figure S5 Frataxin amounts in heart mitochondria of MCK mice
as function of injection route. Hearts from MCK mice were
assayed for frataxin amounts. Note that intraperitoneally (IP)
Injected mice showed the higher amounts of frataxin compared
to subcutaneously (SC), intramuscular (IM) or intravenous (IV).
Values were expressed as picograms/total mitochondrial pro-
tein. N = 3 for each condition.
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